Dual Antagonist Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$606M

Range: $322M - $878M

Total Deal Value

$3.2B

Range: $2.0B - $4.4B

Royalty Rate

14.2% - 23.7%

Tiered up to 27.7%

Dev Milestones

$511M

Range: $328M - $697M

Model Your Deal

Market Analysis

Dual Antagonist therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 dual antagonist asset in immunology & autoimmune is $606M, with total deal values reaching $3.2B. Development milestones average $511M, while regulatory milestones contribute $894M.

The immunology & autoimmune dual antagonist landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for dual antagonist immunology & autoimmune deals range from 14.2% to 23.7% at the base tier, with tiered escalation reaching 18.2%-27.7% on blockbuster sales. Commercial milestones averaging $1.1B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a dual antagonist immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 dual antagonist licensing deals in immunology & autoimmune average $606M in upfront payments, with a range of $322M to $878M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for dual antagonist immunology & autoimmune transactions?

The median total deal value for Phase 2 dual antagonist assets in immunology & autoimmune is $3.2B, ranging from $2.0B to $4.4B. This includes development milestones ($511M), regulatory milestones ($894M), and commercial milestones ($1.1B).

What royalty rates are standard for dual antagonist deals in immunology & autoimmune?

Base royalty rates for dual antagonist immunology & autoimmune transactions range from 14.2% to 23.7%, with tiered escalations reaching 18.2%-27.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in dual antagonist immunology & autoimmune deals?

Dual Antagonist immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($511M) make up the largest share, followed by commercial milestones ($1.1B) and regulatory milestones ($894M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating